Skip to main content
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. — Investor Relations & Filings

Ticker · MEDP ISIN · US58506Q1094 LEI · 549300H8TYEUVTW14A54 US Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2022-09-06 Director's Dealing
Country US United States of America
Listing US MEDP

About Medpace Holdings, Inc.

https://investor.medpace.com/

Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services. The company serves the biotechnology, pharmaceutical, and medical device industries, with a mission to accelerate the development of safe and effective medical therapeutics. Medpace employs a disciplined operating approach that leverages regulatory and therapeutic expertise. Its services include clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core labs. The company has expertise across major therapeutic areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-09-06 English
10-Q
Interim / Quarterly Report Q2 2022
2022-07-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release announcing financial results for the three and six months ended June 30, 2022. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length of the document is 3685 characters, which is relatively short and consistent with a report announcing or furnishing information rather than the full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report filing announcing financial results but not the full earnings release or interim report itself. The press release is incorporated by reference and not fully included in the text. Therefore, the classification is RNS with high confidence.
2022-07-25 English
FORM 4
Director's Dealing
2022-07-20 English
FORM 4
Director's Dealing
2022-07-20 English
FORM 4
Director's Dealing
2022-07-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.